These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 19720288

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC.
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [Abstract] [Full Text] [Related]

  • 3. Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN.
    Visser GW, Klok RP, Gebbinck JW, ter Linden T, van Dongen GA, Molthoff CF.
    J Nucl Med; 2001 Mar; 42(3):509-19. PubMed ID: 11337531
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
    Buchsbaum DJ, Khazaeli MB, Axworthy DB, Schultz J, Chaudhuri TR, Zinn KR, Carpenter M, LoBuglio AF.
    Clin Cancer Res; 2005 Nov 15; 11(22):8180-5. PubMed ID: 16299250
    [Abstract] [Full Text] [Related]

  • 8. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.
    Cancer Res; 1999 Jun 01; 59(11):2635-43. PubMed ID: 10363986
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer.
    Cardillo TM, Ying Z, Gold DV.
    Clin Cancer Res; 2001 Oct 01; 7(10):3186-92. PubMed ID: 11595713
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Preparation and preclinical assessment of folate-conjugated, radiolabelled antibodies.
    Henriksen G, Bruland OS, Larsen RH.
    Anticancer Res; 2005 Oct 01; 25(1A):9-15. PubMed ID: 15816513
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of [131I]I- and [177Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing Prostate Cancer.
    Tsai WK, Zettlitz KA, Dahlbom M, Reiter RE, Wu AM.
    Mol Imaging Biol; 2020 Oct 01; 22(5):1380-1391. PubMed ID: 32661830
    [Abstract] [Full Text] [Related]

  • 13. Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.
    Kraeber-Bodéré F, Bodet-Milin C, Niaudet C, Saï-Maurel C, Moreau A, Faivre-Chauvet A, Thomare P, Deleris G, Estieu-Gionnet K, Bikfalvi A, Barbet J, Paris F.
    J Nucl Med; 2010 Apr 01; 51(4):624-31. PubMed ID: 20351352
    [Abstract] [Full Text] [Related]

  • 14. Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts.
    Wilder RB, Langmuir VK, Mendonca HL, Goris ML, Knox SJ.
    Cancer Res; 1993 Jul 01; 53(13):3022-7. PubMed ID: 8319209
    [Abstract] [Full Text] [Related]

  • 15. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
    Buchsbaum D, Khazaeli MB, Liu T, Bright S, Richardson K, Jones M, Meredith R.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
    [Abstract] [Full Text] [Related]

  • 16. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
    Govindan SV, Shih LB, Goldenberg DM, Sharkey RM, Karacay H, Donnelly JE, Losman MJ, Hansen HJ, Griffiths GL.
    Bioconjug Chem; 1998 Dec 01; 9(6):773-82. PubMed ID: 9815172
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
    Elgqvist J, Andersson H, Bäck T, Hultborn R, Jensen H, Karlsson B, Lindegren S, Palm S, Warnhammar E, Jacobsson L.
    J Nucl Med; 2005 Nov 01; 46(11):1907-15. PubMed ID: 16269606
    [Abstract] [Full Text] [Related]

  • 18. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.
    Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM, Bander NH.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 2):7195s-7200s. PubMed ID: 16203821
    [Abstract] [Full Text] [Related]

  • 19. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ, Khazaeli MB, Mayo MS, Roberson PL.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [Abstract] [Full Text] [Related]

  • 20. Preparation and evaluation of 186/188Re-labeled antibody (A7) for radioimmunotherapy with rhenium(I) tricarbonyl core as a chelate site.
    Ogawa K, Kawashima H, Kinuya S, Shiba K, Onoguchi M, Kimura H, Hashimoto K, Odani A, Saji H.
    Ann Nucl Med; 2009 Dec 01; 23(10):843-8. PubMed ID: 19921351
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.